Progyny, Inc. (NASDAQ:PGNY) Given Consensus Rating of “Hold” by Brokerages

Progyny, Inc. (NASDAQ:PGNY) has been assigned an average recommendation of “Hold” from the twelve research firms that are presently covering the firm, MarketBeat.com reports. Seven analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $23.45.

PGNY has been the topic of several research analyst reports. JPMorgan Chase & Co. lifted their target price on Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Bank of America lifted their target price on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. Canaccord Genuity Group lowered their target price on Progyny from $23.00 to $21.00 and set a “hold” rating on the stock in a research note on Monday. Finally, BTIG Research raised Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a research note on Monday, March 31st.

Progyny Trading Up 0.4%

NASDAQ PGNY opened at $21.95 on Friday. The stock’s 50-day moving average price is $22.03 and its two-hundred day moving average price is $19.68. The company has a market cap of $1.88 billion, a PE ratio of 37.85, a PEG ratio of 2.39 and a beta of 1.37. Progyny has a 1 year low of $13.39 and a 1 year high of $30.42.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.45 by ($0.28). The company had revenue of $324.04 million for the quarter, compared to analyst estimates of $307.86 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. Progyny’s quarterly revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.17 EPS. Research analysts forecast that Progyny will post 0.6 EPS for the current fiscal year.

Institutional Investors Weigh In On Progyny

Several large investors have recently made changes to their positions in the company. New York State Teachers Retirement System grew its stake in shares of Progyny by 0.7% in the 1st quarter. New York State Teachers Retirement System now owns 73,200 shares of the company’s stock valued at $1,635,000 after buying an additional 500 shares in the last quarter. Voya Investment Management LLC grew its stake in shares of Progyny by 1.4% in the 4th quarter. Voya Investment Management LLC now owns 51,792 shares of the company’s stock valued at $893,000 after buying an additional 701 shares in the last quarter. Polen Capital Management LLC grew its stake in shares of Progyny by 0.3% in the 1st quarter. Polen Capital Management LLC now owns 261,506 shares of the company’s stock valued at $5,842,000 after buying an additional 798 shares in the last quarter. Invesco Ltd. boosted its position in Progyny by 0.4% during the first quarter. Invesco Ltd. now owns 275,936 shares of the company’s stock worth $6,164,000 after purchasing an additional 1,117 shares during the period. Finally, GAMMA Investing LLC boosted its position in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after purchasing an additional 1,246 shares during the period. Institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.